Sasaki K, et al. - In patients with FLT3-internal tandem duplication (ITD)–mutated acute myeloid leukemia (AML), researchers assessed outcomes following treatment with sorafenib (a potent multikinase inhibitor with efficacy when given as monotherapy) added to intensive induction chemotherapy. Of 183 newly diagnosed patients, intensive chemotherapy with the addition of sorafenib was received by 79 patients (43%) and intensive chemotherapy alone was received by 104 (57%). After propensity score matching, 42 patients were identified in each cohort. In the sorafenib cohort and in the intensive chemotherapy cohort, the observed overall response rate was 98% and 83%, respectively. Patients with FLT3-ITD–mutated AML experienced improved survival as a result of the addition of sorafenib, irrespective of whether they undergo allogeneic stem cell transplantation.